دورية أكاديمية
Antitumor immune response is associated with favorable survival in GEP-NEN G3.
| العنوان: | Antitumor immune response is associated with favorable survival in GEP-NEN G3. |
|---|---|
| المؤلفون: | Rosery V; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Reis H; Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Savvatakis K; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Kowall B; Center of Clinical Epidemiology, Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany., Stuschke M; Department of Radiotherapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany., Paul A; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.; General, Visceral and Transplantation Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Dechêne A; Department of Gastroenterology and Hepatology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Department of Internal Medicine 6, Paracelsus Medical University, Nürnberg, Germany., Yang J; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Zhao B; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Borgers A; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany., Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany., Cheung PF; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Siveke JT; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany. |
| المصدر: | Endocrine-related cancer [Endocr Relat Cancer] 2021 Sep 02; Vol. 28 (10), pp. 683-693. Date of Electronic Publication: 2021 Sep 02. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioScientifica Country of Publication: England NLM ID: 9436481 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-6821 (Electronic) Linking ISSN: 13510088 NLM ISO Abbreviation: Endocr Relat Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Bristol, UK : BioScientifica Original Publication: Woodlands, Almondsbury, Bristol, UK : Published for the Society of Endocrinology by the Journal of Endocrinology Ltd., 1994- |
| مواضيع طبية MeSH: | Intestinal Neoplasms*/pathology , Neuroendocrine Tumors*/pathology , Pancreatic Neoplasms*/pathology , Stomach Neoplasms*/pathology, B7-H1 Antigen/metabolism ; Humans ; Immunity ; Programmed Cell Death 1 Receptor/metabolism ; Retrospective Studies ; Tumor Microenvironment |
| مستخلص: | The tumor immune microenvironment (TME) represents a key determinant for responses to cancer treatment. However, the immune phenotype of highly proliferative gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is still largely elusive. In this retrospective study, we characterized the TME of high-grade (G3, Ki-67 > 20%) GEP-NEN. We analyzed formalin-fixed paraffin-embedded samples from 37 patients with GEP-NEN G3 by immunohistochemistry and multiplex immunofluorescence to address the abundance and spatial interaction of relevant immune subsets. We focused on the expression of immune checkpoint molecules PD-1 and PD-L1, the cytotoxic T-cell marker CD8, and the tumor-associated macrophage marker CD206. Findings were correlated with overall survival (OS) from the date of a cancer diagnosis. Patients with PD-L1-positive tumors (CPS ≥ 1) and intense PD-1+CD8+ immune cell infiltration showed the most favorable median OS. Multiplex immunofluorescence staining of ten representative tissue samples illustrated intratumoral heterogeneity of PD-L1 expression. Dense PD-1+CD8+ immune cell infiltrates were observed in PD-L1-positive tumor regions but not in PD-L1-negative regions. Proximity analysis revealed a spatial interaction between PD-1+CD8+ cells and PD-L1-positive cells. Our data suggest a pre-existing antitumor immune response in the TME in a subgroup of GEP-NEN G3. This supports a targeted clinical exploration of immunotherapeutic approaches. |
| فهرسة مساهمة: | Keywords: PD-1; PD-L1; checkpoint molecule; gastroenteropancreatic neuroendocrine neoplasm; immune infiltrate; spatial imaging |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 0 (Programmed Cell Death 1 Receptor) |
| تواريخ الأحداث: | Date Created: 20210902 Date Completed: 20220414 Latest Revision: 20220414 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1530/ERC-21-0223 |
| PMID: | 34472429 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1479-6821 |
|---|---|
| DOI: | 10.1530/ERC-21-0223 |